Compared to chemotherapy, alectinib stands out as the pioneering ALK inhibitor that notably enhances disease-free survival (DFS) in postoperative patients diagnosed with IB-IIIA ALK-positive NSCLC (20). The gene discussed is ALK; the disease is non-small cell lung carcinoma.